FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194403670> ?p ?o ?g. }

• W3194403670 endingPage "S44" @default.
• W3194403670 startingPage "S44" @default.
• W3194403670 abstract "Objectives: Advanced vulvar carcinoma typically affects the elderly and treatment options are limited. Moderate antitumor activity of pembrolizumab (ORR, 6%) was noted in a small population of patients (pts) with PD-L1-positive vulvar cancer in the phase 1b KEYNOTE-028 study. KEYNOTE-158 (ClinicalTrials.gov, NCT02628067) is a larger, nonrandomized, multicohort, open-label, phase 2 study that evaluates pembrolizumab in pts with previously treated advanced cancers irrespective of tumor PD-L1 expression. We report results for pts in the vulvar carcinoma cohort receiving pembrolizumab monotherapy. Methods: Enrolled pts were aged ≥18 y with histologically/cytologically documented advanced vulvar squamous cell carcinoma with prior treatment failure; measurable disease per RECIST v1.1; ECOG performance status ≤1; and tumor samples available for biomarker analysis, including PD-L1. PD-L1 positivity was defined as combined positive score ≥1 with expression evaluated using the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, USA). Pts received pembrolizumab 200 mg Q3W until disease progression, unacceptable toxicity, or completion of 35 treatment cycles. Tumor imaging was performed every 9 weeks for 1 y and every 12 weeks thereafter. Response was assessed per RECIST v1.1 by independent central radiologic review. The primary endpoint was ORR. Secondary endpoints included duration of response (DOR), PFS, OS, and safety. Results: A total of 101 pts were enrolled. As of October 5, 2020, median time from start of treatment to data cutoff was 36.0 (range, 15.4–55.2) months. Median age was 64.0 (range, 31–87) y; 9 (8.9%) pts had no prior therapy, 57 (56.4%) had 1, 23 (22.8%) had 2, and 11 (10.9%) had 3 or more lines of prior therapy. Tumors were PD-L1–positive in 84 pts (83.2%), PD-L1–negative in 7 pts (6.9%), and non-evaluable/not assessed in 10 pts (9.9%). Overall, ORR was 10.9% (95% CI, 5.6–18.7); 1 pt had a CR and 10 pts had PR. Among pts with PD-L1–positive tumors, 8 of 84 (9.5%; 95% CI, 4.2–17.9) had CR or PR; among pts with PD-L1–negative tumors, 2 of 7 (28.6%; 95% CI, 3.7–71.0) had CR or PR. Among pts with a response, median DOR was 20.4 months (range, 2.1+ to 28.0). Among all enrolled pts (n=101), median PFS was 2.1 months (95% CI, 2.0–2.1) and median OS was 6.2 months (95% CI, 4.9–9.4 months). Treatment-related AEs occurred in 51 pts (50.5%), including 12 pts (11.9%) who had grade 3–5 events (no event occurred in >1 pt). There were 2 deaths (2.0%) considered related to treatment (hepatitis, n=1; fulminant hepatitis, n=1). Neither pt had comorbidities or pre-existing liver disease to contribute to these events; no other contributing factors were identified. A total of 5 pts (5.0%) discontinued because of treatment-related AEs. Immune-mediated AEs occurred in 18 pts (17.8%). Conclusions: Pembrolizumab monotherapy was associated with durable responses in a subset of pts with vulvar carcinoma (ORR, 10.9%; median DOR, 20.4 months). Responses occurred in both PD-L1-positive and PD-L1-negative pts. Advanced vulvar carcinoma typically affects the elderly and treatment options are limited. Moderate antitumor activity of pembrolizumab (ORR, 6%) was noted in a small population of patients (pts) with PD-L1-positive vulvar cancer in the phase 1b KEYNOTE-028 study. KEYNOTE-158 (ClinicalTrials.gov, NCT02628067) is a larger, nonrandomized, multicohort, open-label, phase 2 study that evaluates pembrolizumab in pts with previously treated advanced cancers irrespective of tumor PD-L1 expression. We report results for pts in the vulvar carcinoma cohort receiving pembrolizumab monotherapy. Enrolled pts were aged ≥18 y with histologically/cytologically documented advanced vulvar squamous cell carcinoma with prior treatment failure; measurable disease per RECIST v1.1; ECOG performance status ≤1; and tumor samples available for biomarker analysis, including PD-L1. PD-L1 positivity was defined as combined positive score ≥1 with expression evaluated using the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies, Carpinteria, CA, USA). Pts received pembrolizumab 200 mg Q3W until disease progression, unacceptable toxicity, or completion of 35 treatment cycles. Tumor imaging was performed every 9 weeks for 1 y and every 12 weeks thereafter. Response was assessed per RECIST v1.1 by independent central radiologic review. The primary endpoint was ORR. Secondary endpoints included duration of response (DOR), PFS, OS, and safety. A total of 101 pts were enrolled. As of October 5, 2020, median time from start of treatment to data cutoff was 36.0 (range, 15.4–55.2) months. Median age was 64.0 (range, 31–87) y; 9 (8.9%) pts had no prior therapy, 57 (56.4%) had 1, 23 (22.8%) had 2, and 11 (10.9%) had 3 or more lines of prior therapy. Tumors were PD-L1–positive in 84 pts (83.2%), PD-L1–negative in 7 pts (6.9%), and non-evaluable/not assessed in 10 pts (9.9%). Overall, ORR was 10.9% (95% CI, 5.6–18.7); 1 pt had a CR and 10 pts had PR. Among pts with PD-L1–positive tumors, 8 of 84 (9.5%; 95% CI, 4.2–17.9) had CR or PR; among pts with PD-L1–negative tumors, 2 of 7 (28.6%; 95% CI, 3.7–71.0) had CR or PR. Among pts with a response, median DOR was 20.4 months (range, 2.1+ to 28.0). Among all enrolled pts (n=101), median PFS was 2.1 months (95% CI, 2.0–2.1) and median OS was 6.2 months (95% CI, 4.9–9.4 months). Treatment-related AEs occurred in 51 pts (50.5%), including 12 pts (11.9%) who had grade 3–5 events (no event occurred in >1 pt). There were 2 deaths (2.0%) considered related to treatment (hepatitis, n=1; fulminant hepatitis, n=1). Neither pt had comorbidities or pre-existing liver disease to contribute to these events; no other contributing factors were identified. A total of 5 pts (5.0%) discontinued because of treatment-related AEs. Immune-mediated AEs occurred in 18 pts (17.8%). Pembrolizumab monotherapy was associated with durable responses in a subset of pts with vulvar carcinoma (ORR, 10.9%; median DOR, 20.4 months). Responses occurred in both PD-L1-positive and PD-L1-negative pts." @default.
• W3194403670 created "2021-08-30" @default.
• W3194403670 creator A5003904683 @default.
• W3194403670 creator A5009613920 @default.
• W3194403670 creator A5015610217 @default.
• W3194403670 creator A5020672869 @default.
• W3194403670 creator A5026538331 @default.
• W3194403670 creator A5029073714 @default.
• W3194403670 creator A5030448011 @default.
• W3194403670 creator A5041066193 @default.
• W3194403670 creator A5043893475 @default.
• W3194403670 creator A5051679715 @default.
• W3194403670 creator A5053725787 @default.
• W3194403670 creator A5055824335 @default.
• W3194403670 creator A5060949051 @default.
• W3194403670 creator A5063825320 @default.
• W3194403670 date "2021-08-01" @default.
• W3194403670 modified "2023-10-02" @default.
• W3194403670 title "Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study" @default.
• W3194403670 doi "https://doi.org/10.1016/s0090-8258(21)00728-9" @default.
• W3194403670 hasPublicationYear "2021" @default.
• W3194403670 type Work @default.
• W3194403670 sameAs 3194403670 @default.
• W3194403670 citedByCount "2" @default.
• W3194403670 countsByYear W31944036702022 @default.
• W3194403670 countsByYear W31944036702023 @default.
• W3194403670 crossrefType "journal-article" @default.
• W3194403670 hasAuthorship W3194403670A5003904683 @default.
• W3194403670 hasAuthorship W3194403670A5009613920 @default.
• W3194403670 hasAuthorship W3194403670A5015610217 @default.
• W3194403670 hasAuthorship W3194403670A5020672869 @default.
• W3194403670 hasAuthorship W3194403670A5026538331 @default.
• W3194403670 hasAuthorship W3194403670A5029073714 @default.
• W3194403670 hasAuthorship W3194403670A5030448011 @default.
• W3194403670 hasAuthorship W3194403670A5041066193 @default.
• W3194403670 hasAuthorship W3194403670A5043893475 @default.
• W3194403670 hasAuthorship W3194403670A5051679715 @default.
• W3194403670 hasAuthorship W3194403670A5053725787 @default.
• W3194403670 hasAuthorship W3194403670A5055824335 @default.
• W3194403670 hasAuthorship W3194403670A5060949051 @default.
• W3194403670 hasAuthorship W3194403670A5063825320 @default.
• W3194403670 hasConcept C121608353 @default.
• W3194403670 hasConcept C126322002 @default.
• W3194403670 hasConcept C141071460 @default.
• W3194403670 hasConcept C143998085 @default.
• W3194403670 hasConcept C203092338 @default.
• W3194403670 hasConcept C2777546739 @default.
• W3194403670 hasConcept C2777701055 @default.
• W3194403670 hasConcept C2779984678 @default.
• W3194403670 hasConcept C2780057760 @default.
• W3194403670 hasConcept C2780370617 @default.
• W3194403670 hasConcept C2781076405 @default.
• W3194403670 hasConcept C2908647359 @default.
• W3194403670 hasConcept C2909580181 @default.
• W3194403670 hasConcept C2994532551 @default.
• W3194403670 hasConcept C31760486 @default.
• W3194403670 hasConcept C535046627 @default.
• W3194403670 hasConcept C71924100 @default.
• W3194403670 hasConcept C99454951 @default.
• W3194403670 hasConceptScore W3194403670C121608353 @default.
• W3194403670 hasConceptScore W3194403670C126322002 @default.
• W3194403670 hasConceptScore W3194403670C141071460 @default.
• W3194403670 hasConceptScore W3194403670C143998085 @default.
• W3194403670 hasConceptScore W3194403670C203092338 @default.
• W3194403670 hasConceptScore W3194403670C2777546739 @default.
• W3194403670 hasConceptScore W3194403670C2777701055 @default.
• W3194403670 hasConceptScore W3194403670C2779984678 @default.
• W3194403670 hasConceptScore W3194403670C2780057760 @default.
• W3194403670 hasConceptScore W3194403670C2780370617 @default.
• W3194403670 hasConceptScore W3194403670C2781076405 @default.
• W3194403670 hasConceptScore W3194403670C2908647359 @default.
• W3194403670 hasConceptScore W3194403670C2909580181 @default.
• W3194403670 hasConceptScore W3194403670C2994532551 @default.
• W3194403670 hasConceptScore W3194403670C31760486 @default.
• W3194403670 hasConceptScore W3194403670C535046627 @default.
• W3194403670 hasConceptScore W3194403670C71924100 @default.
• W3194403670 hasConceptScore W3194403670C99454951 @default.
• W3194403670 hasLocation W31944036701 @default.
• W3194403670 hasOpenAccess W3194403670 @default.
• W3194403670 hasPrimaryLocation W31944036701 @default.
• W3194403670 hasRelatedWork W2760940301 @default.
• W3194403670 hasRelatedWork W2982155686 @default.
• W3194403670 hasRelatedWork W3036571927 @default.
• W3194403670 hasRelatedWork W3094659495 @default.
• W3194403670 hasRelatedWork W3100080748 @default.
• W3194403670 hasRelatedWork W3177224496 @default.
• W3194403670 hasRelatedWork W3194403670 @default.
• W3194403670 hasRelatedWork W3213977202 @default.
• W3194403670 hasRelatedWork W4304690509 @default.
• W3194403670 hasRelatedWork W4322775203 @default.
• W3194403670 hasVolume "162" @default.
• W3194403670 isParatext "false" @default.
• W3194403670 isRetracted "false" @default.
• W3194403670 magId "3194403670" @default.
• W3194403670 workType "article" @default.